Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | STK25 | O00506 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22420088 | 0.76 | CYP1A2 (0.31) | — | |
| SCHEMBL10065610 | 0.72 | GFER (0.37) | GFERATMMAPK14MAPTSTK25 | |
| SCHEMBL1205789 | 0.70 | HPGD (0.46) | GFERATMMAPK14STK25 | |
| SCHEMBL24175286 | 0.70 | — | — | |
| SCHEMBL21719718 | 0.68 | KDM5B (0.33) | GFERATMMAPK14STK25 | |
| SCHEMBL21719245 | 0.68 | ATM (0.39) | GFERATMMAPK14STK25 | |
| SCHEMBL20681841 | 0.68 | MAPK14 (0.38) | GFERATMMAPK14STK25 | |
| SCHEMBL21719409 | 0.68 | GFER (0.36) | GFERATMMAPK14STK25 | |
| SCHEMBL1496278 | 0.68 | — | — | |
| SCHEMBL1531104 | 0.68 | MAPK14 (0.38) | GFERATMMAPK14MAPTSTK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | AXL 4604/4885KEAP1 929/4885TRPM8 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.